AstraZeneca's vaccine rollout nets $275m in sales - but drags on its profits

Today's quarterly results from AstraZeneca are a very timely reminder that, for all the debate about the drug-maker's involvement in the Oxford COVID vaccine, it is of very little importance to the financial fortunes of what is currently the fifth-largest company in the FTSE 100.

The full article is no longer available.